| (Values in U.S. Thousands) | Mar, 2023 | Mar, 2022 | Mar, 2021 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 3,880 | 730 | 0 | 0 |
| Sales Growth | -100.00% | +431.51% | unch | unch | unch |
| Net Income | -36,680 | -43,630 | -17,520 | 0 | 0 |
| Net Income Growth | +15.93% | -149.03% | unch | unch | unch |
Reunion Neuroscience Inc (REUN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Reunion Neuroscience Inc. is involved in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes. The Company's lead asset consist RE-104. Reunion Neuroscience Inc., formerly known as Field Trip Health Ltd., is based in TORONTO.
Fiscal Year End Date: 03/31